Hepatic Encephalopathy  >>  Xifaxan (rifaximin) 
Welcome,         Profile    Billing    Logout  

10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
2018-004323-37: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-centre randomized, double blind, placebo controlled trial. The PEARL trial

Not yet recruiting
4
238
Europe
Xifaxan, Lactulose, Tablet, Syrup, Xifaxan, Lactulose
Academic Medical Centre, Academic Medical Centre, ZonMw, Norgine B.V.
post-TIPS Hepatic Encephalopathy (HE), Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt placement, Diseases [C] - Symptoms and general pathology [C23]
 
 
PEARL, NCT04073290: Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

Recruiting
4
238
Europe
Rifaximin 550 milligram Oral Tablet [XIFAXAN], TARGAXAN, Placebo oral tablet, Placebo, Lactulose 667 milligram/milliliter Oral Solution, Lactulose syrup
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Universitaire Ziekenhuizen Leuven, Norgine
Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases, Pathological Processes
09/22
09/23
NCT04244877: Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility

Withdrawn
3
20
NA
Rifaximin, Xifaxan
MetroHealth Medical Center
Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth, Gastrointestinal Motility Disorder
05/23
12/23
NCT05754996: Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy

Recruiting
3
102
RoW
Nifuroxazide, Lactulose, Rifaximin 550Mg Tab
Cairo University
Hepatic Encephalopathy
12/24
12/24
RED-C-3131, NCT05071716: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruiting
3
524
Canada, US, RoW
Rifaximin SSD, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
09/25
09/25
RED-C-3132, NCT05297448: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruiting
3
466
Europe, Canada, US, RoW
Rifaximin SSD, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
01/26
01/26
NCT04161053: Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Recruiting
3
60
RoW
Rifaximin, Gastrobiotic, Trencedia, Nitazoxanide, Nanazoxid
Tanta University
Hepatic Encephalopathy
11/28
12/28
NCT05786859: The Efficacy and Safety of Rifaximin Treatment

Recruiting
1
124
RoW
Rifaximin 200 mg, Standard Treatment without Rifaximin
Sun Yat-sen University
Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV, Hepatitis B, Rifaximin, Effect of Drug
07/25
10/25
ChiCTR2000040960: Comparison of probiotics and rifaximin in the prevention and treatment of minimal hepatic encephalopathy and their effects on intestinal flora in patients with liver cirrhosis

Recruiting
N/A
60
 
3 bid capsules of Bifidobacterium Triple Live bacteria ;Rifaximin0.6g, bid ;Lactulose (Adjust freely according to the number of stools)
Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University; Level of the institution：, The science and technology Department of Anhui Province
minimal hepatic encephalopathy
 
 

Download Options